dm+d
16602005
Articles
Switching between oral prednisolone and IV hydrocortisone
29 September 2023
Hydrocortisone: informing intrathecal risk assessment
11 August 2022
Hydrocortisone products vary in their licensed status and other characteristics which affects their suitability for intrathecal administrationHydrocortisone acetate: informing intrathecal risk assessment
11 August 2022
Hydrocortisone acetate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administrationRefrigerated Storage
Timodine
Alliance PharmaceuticalsAlliance Pharmaceuticals
Timodine
Cream (contains nystatin, dimeticone, hydrocortisone and benzalkonium chloride)
Contact Alliance Pharmaceuticals in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
19 March 2021
London MI Service
Hydrocortisone
Colonis PharmaColonis Pharma
Hydrocortisone
Oral solution (5mg/5mL, 10mg/5mL)
Contact Colonis Pharma in all cases where a deviation from the recommended storage conditions has occurred.
Refer to the electronic medicines compendium (eMC) at https://www.medicines.org.uk for company contact details.
13 October 2022
London MI Service
Medicine Compliance Aid Stability
generic
Accord-UK Ltd
Accord-UK Ltd
generic
Tablets 10mg, 20mg
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Store in airtight containers.
20 December 2022
Plenadren
ViroPharma Ltd
ViroPharma Ltd
Plenadren
Tablets m/r 5mg, 20mg
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Store in airtight containers.
22 November 2022
Non-proprietary
Accord-UK Ltd
Accord-UK Ltd
Non-proprietary
Tablets mucoadhesive buccal 2.5mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Mucoadhesive buccal tablets.
20 December 2022
Lactation Safety Information
Oral / parenteral
Oral / parenteral
No published evidence of safety
Normal component of breast-milk
Used in full-term neonates from birth
Doses up to 160mg daily unlikely to cause adverse effects in the infant
9 November 2020
Local injection
Local injection
11 September 2020
In the ear
In the ear
Only available in combination with gentamicin for which there are no additional risks
11 September 2020
Orophayngeal -
buccal tablets
Orophayngeal -
buccal tablets
11 September 2020
Topical
Topical
Low potency
There are no additional risks when used in combination topical preparations containing antimicrobials or urea
11 September 2020
Rectal
for inflammatory bowel disease
Rectal
for inflammatory bowel disease
-
No published evidence of safety after rectal administration
Small amounts in breast milk after oral administration
Doses up to 50mg orally daily unlikely to cause adverse effects in the infant
11 September 2020